In Addis Ababa, a quiet study of 334 women who felt entirely well has surfaced a warning that silence does not mean safety: one in five HIV-positive women carry high-risk HPV, a virus that, in bodies where immunity is already strained, does not leave but transforms. The findings, drawn from Ethiopia's largest specialized hospital, place a familiar tragedy in sharper focus — cervical cancer, the leading cancer killer of women across Sub-Saharan Africa, is seeded long before it announces itself. Science has mapped the danger; what remains is the will to act before the cells do.
HPV infections and cervical abnormalities widespread among HIV-positive women in Ethiopia
HIV-positive women in Ethiopia face elevated cervical cancer risk from persistent HPV infection, a leading cancer death cause in Sub-Saharan Africa.
The virus works silently. By the time a woman feels sick, the cancer is often advanced.
Mark
Why does HIV make women so much more vulnerable to HPV in the first place?
Mimi
The immune system normally clears HPV on its own within a year or two. But HIV damages the very cells that mount that defense—CD4 cells. Without them, the virus persists, integrates into cervical tissue, and has years to cause damage.
Mark
So these women in the study—they didn't know they had HPV?
Mimi
Exactly. They had no symptoms. That's why screening matters so much. The virus works silently. By the time a woman feels sick, the cancer is often advanced.
Mark
The study found HPV35 and HPV16 most common. Does that change how we vaccinate?
Mimi
It complicates things. Current vaccines protect against HPV16 and 18, but HPV35 is also dangerous and less covered. That's why vaccination alone won't solve this—screening has to happen too.
Mark
What about the condom finding? That seems almost too simple.
Mimi
It's not simple at all. It means prevention works, but only if women have the power to negotiate condom use, access to them, and knowledge about why they matter. That's a much bigger conversation than just handing out condoms.
Mark
If one in five women in this study had HPV, what does that mean for the broader population in Ethiopia?
Mimi
This was a hospital-based sample, so it might be higher than the general population. But even if the true rate is lower, we're talking about thousands of women at risk. The infrastructure to screen and treat them barely exists.
Il Polso
- One in five asymptomatic HIV-positive women in Addis Ababa tested positive for high-risk HPV — a hidden epidemic unfolding in bodies that feel perfectly healthy.
- Among those infected, abnormal cervical cell changes appeared nearly three times more often than in uninfected women, with some already showing precancerous high-grade lesions requiring immediate intervention.
- Non-16/18 HPV strains — particularly HPV35 — dominated the infections, raising pointed questions about whether current vaccines, designed largely around Western strain profiles, will adequately protect this population.
- Condom use emerged as a statistically significant protective factor, offering a concrete, deployable prevention lever even where vaccines and screening infrastructure remain scarce.
- Researchers are calling screening, vaccination, and safe-sex education not aspirational goals but urgent necessities — the virus is already present, and the health system's window to intercept it is narrowing.
In Addis Ababa, a quiet study of 334 women who felt entirely well has surfaced a warning that silence does not mean safety: one in five HIV-positive women carry high-risk HPV, a virus that, in bodies where immunity is already strained, does not leave but transforms. The findings, drawn from Ethiopia's largest specialized hospital, place a familiar tragedy in sharper focus — cervical cancer, the leading cancer killer of women across Sub-Saharan Africa, is seeded long before it announces itself. Science has mapped the danger; what remains is the will to act before the cells do.
Cervical cancer is the deadliest cancer among women in Sub-Saharan Africa, and it almost always begins the same way: a persistent HPV infection that a healthy immune system would ordinarily clear. For women living with HIV, that clearance often fails. The virus stays, settles, and slowly alters cervical tissue — usually without any symptoms at all.
To understand how widespread this threat had become, researchers in Addis Ababa recruited 334 HIV-positive women from Tikur Anbessa Specialized Hospital — all asymptomatic, all apparently well. Cervical samples were tested for 14 HPV types using real-time PCR, and Pap smears were performed to detect cellular changes. The results were sobering: 20.6 percent of the women carried high-risk HPV, with HPV35 and HPV16 as the most prevalent strains — a distribution that carries implications for which vaccines will offer meaningful protection in this region.
The cellular damage was already visible. Among HPV-positive women, 36.1 percent showed abnormal cytology, compared to 12.6 percent of those without the virus. Nearly seven percent had high-grade precancerous lesions — changes that do not always progress to cancer, but can, and that demand clinical follow-up. None of these women had sought care for symptoms. Most would never have known.
One protective signal emerged clearly from the data: consistent condom use was associated with significantly lower rates of both infection and abnormal cell changes, affirming that behavioral prevention, combined with screening and vaccination, could meaningfully alter outcomes. The researchers concluded that for HIV-positive women in Ethiopia — and across Sub-Saharan Africa — these interventions are not future priorities. The virus is already present. The question is whether the systems meant to catch it will arrive in time.
Cervical cancer kills more women in Sub-Saharan Africa than any other malignancy. The disease almost always begins with a persistent infection from human papillomavirus—HPV—a virus that spreads through sexual contact and that the immune system usually clears on its own. But for women living with HIV, whose immune systems are already compromised, HPV lingers. It settles into cervical tissue. It transforms cells. It waits.
In Addis Ababa, researchers wanted to understand how widespread this danger actually was. They recruited 334 women living with HIV from the Tikur Anbessa Specialized Hospital—women who had no symptoms, no obvious signs of disease. They collected cervical samples and ran them through real-time PCR testing, looking for 12 types of high-risk HPV and 2 low-risk types. They also performed Pap smears to check for abnormal cell changes. The goal was straightforward: map the problem so something could be done about it.
What they found was sobering. One in five of these women—20.6 percent—carried high-risk HPV. The most common strains were HPV35, present in 16.8 percent of the group, and HPV16, found in 14.7 percent. These numbers matter because they tell a story about which variants are circulating in this population and which vaccines might or might not protect against them. But the real alarm came when researchers looked at what the virus was doing to cervical tissue.
Among women who tested positive for high-risk HPV, more than one in three showed abnormal cell changes on their Pap smears—36.1 percent compared to just 12.6 percent of women without the virus. The difference was statistically unmistakable. Within the HPV-positive group, 9.9 percent had low-grade lesions and 6.6 percent had high-grade lesions, the kind that can progress to invasive cancer if left untreated. For context: high-grade lesions are considered precancerous. They don't always become cancer, but they can, and they require intervention.
The researchers used statistical modeling to identify what factors reduced risk. One finding stood out: women who used condoms had significantly lower odds of both HPV infection and abnormal cytology. It was a concrete piece of evidence that prevention works—that behavior change, paired with other interventions, could actually shift the trajectory of disease in this population.
What makes this study important is not just the numbers themselves but what they reveal about a gap in care. These were asymptomatic women—they felt fine, had no complaints. Yet one in five carried a virus that could eventually kill them, and more than one in three of those infected already showed cellular changes. Most of these women would never know it without screening. And in Ethiopia, as in much of Sub-Saharan Africa, cervical cancer screening programs remain sparse and inconsistently available. Vaccination against HPV exists but is not yet widely deployed in the region. The researchers concluded that strengthened screening, broader vaccination campaigns, and sustained education about safe-sex practices are not optional—they are urgent. The virus is already there. The question is whether the health system will catch it in time.
Citazioni salienti
The virus is already there. The question is whether the health system will catch it in time.— Study findings on cervical cancer screening urgency in Ethiopia
Vuoi la storia completa?
Leggi l'originale su Nature ↗
Health & Medicine